Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 11/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13074863 | 0.84 | SLC6A4 (0.50) | SLC6A4SLC6A2SLC6A3CYP2D6ALDH1A1 | |
| SCHEMBL6770906 | 0.84 | SLC6A4 (0.53) | SLC6A4SLC6A2SLC6A3CYP2D6CYP3A4 | |
| SCHEMBL759261 | 0.83 | SLC6A4 (0.49) | SLC6A4SLC6A2SLC6A3CYP2D6ALDH1A1 | |
| SCHEMBL9880971 | 0.82 | SLC6A2 (0.43) | SLC6A4SLC6A2SLC6A3CYP2D6ALDH1A1 | |
| SCHEMBL4716938 | 0.80 | SLC6A4 (0.52) | SLC6A4SLC6A2SLC6A3CYP2D6ALDH1A1 | |
| SCHEMBL6770900 | 0.77 | SLC6A4 (0.44) | SLC6A4SLC6A2SLC6A3CYP2D6ALDH1A1 | |
| SCHEMBL6770904 | 0.77 | ALDH1A1 (0.46) | SLC6A4SLC6A2SLC6A3CYP2D6ALDH1A1 | |
| SCHEMBL24303162 | 0.76 | SLC6A4 (0.51) | SLC6A4SLC6A2SLC6A3CYP2D6ALDH1A1 | |
| SCHEMBL16649650 | 0.76 | SLC6A4 (0.51) | SLC6A4SLC6A2SLC6A3CYP2D6ALDH1A1 | |
| SCHEMBL16650025 | 0.76 | SLC6A4 (0.51) | SLC6A4SLC6A2SLC6A3CYP2D6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135984-A1 | DUAL-ACTION INHBITORS AND METHODS OF USING SAME | AERIE PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135984-A1 | DUAL-ACTION INHBITORS AND METHODS OF USING SAME | SLC6A2, ROCK2, SLC6A4 | SLC6A4 3/4885SLC6A2 1/4885SLC6A3 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.